Install
DocWire News delivers the latest health care news, research, and trends in medicine, giving health care professionals access to the curated content most relevant to their fields.
- 61articles · 30d
- 1+ day agolatest article
- Aug 17, 2026earliest in window
- 97%with images
- 264avg words
- Health & Wellness 61
- Medical 58
- Health 56
- Education 2
- Finance & Business 2
- Economy, Business & Finance 1
- Labour 1
- Politics 1
Please confirm you are human
This browser or connection looks automated. Press and continuously hold the control for 3 seconds to enable Google-hosted web results and, when separately allowed, AI-assisted answers.
A successful check enables 100 search requests. Interactive access does not authorize scraping, systematic collection, or reuse of search output.
News
Biparatopic HER2 Targeting in Action: Anbenitamab???s Phase 3 Breakthrough
3+ day, 11+ hour ago (38+ words) Biparatopic HER2 Targeting in Action: Anbenitamab’s Phase 3 Breakthrough Docwire News Biparatopic HER2 Targeting in Action: Anbenitamab’s Phase 3 Breakthrough Shao ZM, et al. Basch E, et al. 2026 American Society of Clinical Oncology Annual Meeting. Abstract LBA660....
Ustekinumab May Fill Unmet Need for Pediatric Ulcerative Colitis
3+ day, 11+ hour ago (290+ words) Jeffrey Hyams, MD, of the University of Connecticut and Connecticut Children’s Hospital in Hartford, Connecticut, shares results from the UNIFI JR trial evaluating ustekinumab in pediatric patients with ulcerative colitis who did not respond to conventional therapies. From these results…...
Balancing Disease Control and Safety for Older Adults With IBD
3+ day, 11+ hour ago (146+ words) Adam Faye, MD, of NYU Langone Health, New York, New York, shares results from a study evaluating the safety of guselkumab among older populations of patients with immune-mediated inflammatory diseases, such as inflammatory bowel disease (IBD), psoriasis, and psoriatic arthritis....
SYNCHRONIZE Findings Highlight Metabolic Benefits Beyond Weight Loss
3+ day, 11+ hour ago (427+ words) The following transcript has been edited for clarity. Can you elaborate a little on what the results tell us about survodutide’s unique dual glucagon/GLP-1 mechanism? Dr. Le Roux: Yeah, because survodutide acts like an oxyntomodulin analog, a natural gut…...
Evidence of Role of Microbiota-Metabolite Axis in TNBC Points to Need for Translational Research
5+ day, 5+ hour ago (294+ words) The development of immune checkpoint inhibitors, specifically pembrolizumab used alone or in combination with chemotherapy, has improved outcomes for selected patients with triple-negative breast cancer (TNBC). Despite this success, patients still develop primary or acquired resistance. In a recent review…...
Q&A: TEMPO-2 Investigators on Tavapadon in Early Parkinson's Disease
1+ week, 5+ day ago (350+ words) Cindy Zadikoff, MD, MSc, executive medical director at AbbVie, discusses recent results of the TEMPO-2 trial. Here, she shares what tavapadon use means for clinicians treating early Parkinson’s disease, how to balance tolerability and efficacy in clinical practice, the drug’s…...
Efgartigimod Shows Efficacy for Treating Severe Myasthenia Gravis Exacerbations
3+ week, 4+ day ago (226+ words) Therapies currently used to treat myasthenia gravis (MG) are limited by their short-term efficacy and may not be readily available in plasma exchange settings. In light of this, other approaches to treating MG are needed. In a prospective study published…...
Study Finds 5-Minute Educational Video Fails to Increase COVID Vaccine Willingness
3+ week, 4+ day ago (221+ words) The study, conducted in the second year of vaccine distribution, included 639 individuals selected from the German general population. Participants had a mean age of 37.04 years, 77.8% were female, and 24.4% self-reported a mental illness. Initially, 715 individuals participated in the study, but 76 were…...